新築股份(002480.SZ):四川紓困發展基金完成增持0.47%股份
格隆匯7月19日丨新築股份(002480.SZ)公吿稱,公司控股股東四川發展擬指定其控制的川發展證券基金管理的四川資本市場紓困發展證券投資基金合夥企業(有限合夥)(簡稱“四川紓困發展基金”),通過集中競價交易方式增持公司股份。此次擬增持數量不超過376.848萬股(佔公司總股本的0.49%),不低於188.424萬股;實施期限為2022年4月2日起6個月內擇機完成。
2022年7月5日至2022年7月18日收市,四川紓困發展基金通過集中競價方式累計增持公司股份364.87萬股,佔公司總股本的0.47%,累計增持金額2000.31萬元,該次增持股份計劃已實施完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.